Osilodrostat in Cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored
Author:
Affiliation:
1. Department of Endocrinology, Aix Marseille Univ, APHM, INSERM, MMG, Marmara Institute La Conception Hospital Marseille France
Publisher
Wiley
Subject
Endocrinology, Diabetes and Metabolism,Endocrinology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/cen.14551
Reference5 articles.
1. LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study
2. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease
3. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
4. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing’s syndrome other than Cushing’s disease
5. Approach to the Patient Treated with Steroidogenesis Inhibitors
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Medical Therapy of Endogenous Cushing’s Syndrome with Steroidogenesis Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic Effects;Experimental and Clinical Endocrinology & Diabetes;2024-04-30
2. A Case of an Ectopic ACTH-Producing Tumor With Adrenal Shrinkage During Osilodrostat Administration;JCEM Case Reports;2024-01-08
3. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism;European Journal of Endocrinology;2023-12-20
4. Cushing’s Disease: Long-Term Effectiveness and Safety of Osilodrostat in a Polish Group of Patients with Persistent Hypercortisolemia in the Experience of a Single Center;Biomedicines;2023-12-06
5. Pharmacological Treatment of Cushing's Syndrome;Archives of Medical Research;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3